Floatz logo

Palbociclib

EGFR Gene Amplification

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the EGFR Gene Amplification cohort.

Asset / SponsorPhaseRating
FLUDEOXYGLUCOSE
Jonsson Comprehensive Cancer Center
Phase 2B
Metformin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2B
Gefetinib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2B
Osimertinib
Jonsson Comprehensive Cancer Center
Phase 2B
Neratinib
M.D. Anderson Cancer Center
Phase 1CC

View all 11 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →